Guan Cha Zhe Wang·2025-12-27 05:20Core Viewpoint - The insider trading case involving Jiang Wei, the actual controller of Haohai Biological Technology (688366.SH), has concluded with a total penalty of 19.34 million yuan, highlighting governance concerns within the company as it faces growth challenges and declining performance [1][2][5]. Group 1: Insider Trading Case - Jiang Wei was penalized by the China Securities Regulatory Commission (CSRC) for insider trading and advising others to trade securities, resulting in a total fine and confiscation of 19.34 million yuan [1][5]. - The investigation lasted seven months, reflecting the current regulatory environment's strict stance against insider trading, with half of the CSRC's administrative penalties this year related to such cases [5][7]. - Jiang Wei has never held a position in the listed company and does not participate in daily operations, yet he and his wife control 45.82% of the company's shares [1][5]. Group 2: Company Performance and Governance - Haohai Biological Technology is experiencing a growth bottleneck, with 2024 revenue at 2.698 billion yuan, a mere 1.64% increase, marking the first single-digit growth since 2021 [2][10]. - The company has seen a decline in both revenue and net profit in the first three quarters of 2025, with revenue down 8.47% and net profit down over 10% [2]. - The governance structure is questioned as Jiang Wei's influence persists despite his absence from operational roles, raising concerns about the "behind-the-scenes boss" model [8][12]. Group 3: Business Challenges - The company faces significant challenges in its ophthalmology segment, with revenue from artificial lenses down 14.06% and viscoelastic agents down 19.53% due to centralized procurement policies [10]. - Although the aesthetic medicine segment remains a growth driver, the growth rate of hyaluronic acid products has sharply decreased from 95.45% in 2023 to 23.23% [10]. - Haohai is attempting to diversify by acquiring a 19.8% stake in Ruijie Biological for 38.35 million yuan, despite the target company being in a loss-making state [10].